Upstream Bio (UPB) Gains from Investment Securities (2023 - 2026)

Upstream Bio's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 1450.0% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.3 million (changed N/A YoY), while the FY2025 annual figure was $8.0 million, up 22.65% from the prior year.
• Gains from Investment Securities was $3.1 million for Q1 2026 at Upstream Bio, down from $8.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $8.3 million in Q2 2025 to a low of $3000.0 in Q4 2023.
• Historically, Gains from Investment Securities has averaged $4.1 million across 4 years, with a median of $3.1 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities surged 636.84% in 2025, then soared 1450.0% in 2026.
• A 4-year view of Gains from Investment Securities shows it stood at $3000.0 in 2023, then soared by 36709.33% to $1.1 million in 2024, then jumped by 620.9% to $8.0 million in 2025, then slumped by 61.06% to $3.1 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.1 million (Q1 2026), $8.0 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.